Loading clinical trials...

Proteomic Profiling in Diagnosing Non-Small Cell Lung Cancer in Patients Who Are Undergoing Lung Resection for Suspicious Stage I Lung Lesions | Clinical Trials | Clareo Health

COMPLETED

Proteomic Profiling in Diagnosing Non-Small Cell Lung Cancer in Patients Who Are Undergoing Lung Resection for Suspicious Stage I Lung Lesions

Use Of Proteomic Analysis Of Serum Samples For Detection Of Non-Small Cell Lung Cancer

NCT00077324•Alliance for Clinical Trials in Oncology

View on ClinicalTrials.gov

Summary

RATIONALE: Evaluating specific proteins in the blood may be an effective and noninvasive procedure to help doctors determine if a patient has early non-small cell lung cancer. PURPOSE: This clinical trial is studying proteomic profiling to see how well it works in diagnosing non-small cell lung cancer in patients who are undergoing resection for suspicious (abnormal) stage I lung lesions.

Detailed Description

OBJECTIVES: Primary * Determine, prospectively, whether serum proteomic profiling can predict the presence of primary non-small cell lung cancer in patients with clinically suspicious stage I lung lesions who are undergoing lung resection. Secondary * Correlate the serum proteomic profile with pathologic nodal status and histopathologic features of primary lung cancer in these patients. * Correlate the initial and follow-up serum proteomic profile with overall and cancer-specific survival of these patients. * Correlate changes in the proteomic profile (preoperative to postoperative) with overall and cancer-specific survival of these patients. Tertiary * Determine whether novel molecular strategies can predict the presence of lung cancer and/or the biologic behavior of an individual cancer in these patients.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Patient must be ≥18 years of age.
•2. Patient must have a clinically suspicious stage I (cT1-2 N0 M0) lung lesion.
•3. Patient must have pre-operative imaging procedures within 60 days prior to the date of the lung resection: Helical CT scan of the chest and CT scan of the upper abdomen, including the liver and adrenal glands (with or without IV contrast), as clinically indicated. The helical CT must rule out metastatic disease in the liver and adrenal glands.
•4. Patient, or the patient's legally acceptable representative, must provide a signed and dated written informed consent PRIOR to registration and any study-related procedures being performed.
•5. Patient must provide written authorization to allow the use and disclosure of their protected health information. NOTE: This may be obtained in either the study-specific informed consent or in a separate authorization form and must be obtained from the patient PRIOR to registration and any study-related procedures being performed.
•6. If patient is a survivor of a prior cancer, the following criteria are met:
•1. Patient has undergone potentially curative therapy for all prior malignancies,
•2. No evidence of any prior malignancies for at least 5 years with no evidence of recurrence (except for effectively treated basal cell or squamous carcinoma of the skin, carcinoma in-situ of the cervix that has been effectively treated by surgery alone, or lobular carcinoma in-situ of the ipsilateral or contralateral breast treated by surgery alone),
•3. Patient is deemed by their treating physician to be at low risk for recurrence from prior malignancies.

Exclusion Criteria

•1. Patient has undergone previous lung resection within the preceding 30 days.
•2. Patient has received prior chemotherapy or radiotherapy.
•3. Patient has had a blood product transfusion of any kind within the past 60 days of the operative procedure.

Locations (73)

University of Alabama at Birmingham Comprehensive Cancer Center

Birmingham, Alabama, United States

John Muir/Mount Diablo Cancer Center - Concord Campus

Concord, California, United States

City of Hope Comprehensive Cancer Center

Duarte, California, United States

Glendale Memorial Hospital Comprehensive Cancer Center

Glendale, California, United States

Veterans Affairs Medical Center - Loma Linda (Pettis)

Loma Linda, California, United States

Sutter Cancer Center at Roseville Medical Center

Roseville, California, United States

Sutter Cancer Center

Sacramento, California, United States

John Muir/Mt. Diablo Comprehensive Cancer Center

Walnut Creek, California, United States

Praxair Cancer Center at Danbury Hospital

Danbury, Connecticut, United States

George Washington University Medical Center

Washington D.C., District of Columbia, United States

Key Dates

Start Date

February 1, 2004

Primary Completion Date

November 1, 2011

Completion Date

November 1, 2011

Last Updated

July 6, 2016

Enrollment

1,000

ACTUAL participants

Conditions

Lung Cancer

Interventions

proteomic profiling

GENETIC

surface-enhanced laser desorption/ionization-time of flight mass spectrometry

OTHER

biopsy

PROCEDURE

surgery

PROCEDURE

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

NCT06498635

Lung Non-Small Cell CarcinomaStage II Lung Cancer AJCC v8+2 more

View study

RECRUITINGPHASE1

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

NCT06066138

Locally Advanced Alveolar Soft Part SarcomaMetastatic Alveolar Soft Part Sarcoma+8 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 6, 2016Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Proteomic Profiling in Diagnosing Non-Small Cell Lung Cancer in Patients Who Are Undergoing Lung Resection for Suspicious Stage I Lung Lesions

Inclusion Criteria

Exclusion Criteria

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

Reducing the Incidence of Symptomatic Brain Metastases With MRI Surveillance

Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)

Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer

A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)